By Dr. Salman Ahmad Bajwa, MBBS, DHPE | Vaccinology Consultant | Vaccine.pk
Meta Description: Learn about Respiratory Syncytial Virus (RSV) in infants, including symptoms, diagnosis, latest CDC recommendations, prevention strategies, and new monoclonal antibody treatments for high-risk babies.
Table of Contents
What is RSV?
Why Infants Are at Risk
RSV Symptoms and When to Seek Care
Latest Recommendations for RSV Prevention (2024-2025)
Diagnosis Methods
Treatment Options Including New Therapies
Prevention Strategies
RSV vs. Other Respiratory Illnesses
Long-term Effects and Complications
Frequently Asked Questions
1. What is RSV? Understanding Respiratory Syncytial Virus
Respiratory Syncytial Virus (RSV) is a common contagious virus that infects the lungs and breathing passages. Almost all children contract RSV by age 2, making it one of the most frequent causes of lower respiratory tract infections in infants and young children worldwide.
Crowded living conditions, air pollution, secondhand smoke
Breastfeeding Status
Lack of passive maternal antibodies increases risk
Daycare/Sibling Exposure
Increased exposure to respiratory pathogens
Research Finding: Hospitalization rates for RSV are 5-40 times higher in infants with chronic lung disease compared to healthy term infants (American Academy of Pediatrics, 2023).
3. RSV Symptoms and When to Seek Care
RSV typically begins with upper respiratory symptoms before progressing to lower respiratory involvement.
Classic Symptom Progression in Infants:
Early Signs (Days 1-3):
Runny or stuffy nose
Sneezing
Cough
Low-grade fever (not always present in very young infants)
Decreased appetite or difficulty feeding
Irritability or lethargy
Progressive Signs (Days 3-7):
Increased cough, often with wheezing or whistling sound
Rapid, labored breathing
Retractions (skin pulling in around ribs and neck)
Flaring of nostrils with each breath
Grunting with respirations
Poor feeding; dehydration risk
Severe Symptoms Requiring Emergency Care:
Seek immediate medical attention if your infant shows:
Severe respiratory distress (marked retractions, grunting, nasal flaring)
Cyanosis (bluish discoloration of lips, mouth, or fingernails)
Apnea (pauses in breathing)
Inability to drink fluids; signs of dehydration
Lethargy or unresponsiveness
Oxygen saturation < 92% on room air
Respiratory rate > 70 breaths per minute (in infants < 2 months)
4. Latest Recommendations for RSV Prevention (CDC & AAP 2024-2025)
New RSV Vaccine (2024 Authorization)
In 2023-2024, the FDA approved the first RSV vaccine for use in older adults (GSK’s Arexvy for ages ≥60). While this doesn’t directly prevent RSV in infants, it protects high-risk infants by reducing exposure from vaccinated caregivers.
Recommendation: Older caregivers and grandparents in close contact with high-risk infants should consider RSV vaccination per CDC guidance.
Monoclonal Antibody Prophylaxis – Nirsevimab (NEW 2024)
Major Update: FDA expanded approval of nirsevimab (Beyfortus) for RSV prophylaxis in all infants during their first RSV season, with special emphasis on high-risk populations.
Nirsevimab Guidelines:
Eligibility:
All infants < 8 months of age at the start of RSV season (July 1 – June 30)
Premature infants (≤29 weeks gestation) up to 12 months during first RSV season
Children 12-24 months with chronic lung disease or congenital heart disease
Immunocompromised children up to 24 months
Dosing:
Single dose: 100 mg IM (< 5 kg) or 200 mg IM (≥ 5 kg)
Administered during RSV season
Can be given alongside routine vaccinations at different anatomical sites
Efficacy:
75-80% reduction in RSV-caused lower respiratory tract disease requiring hospitalization
Well-tolerated with minimal adverse effects
Creates immediate, short-term immunity lasting RSV season
Clinical Significance: Nirsevimab represents the first effective prevention strategy for all infants during RSV season, fundamentally changing preventive approach.
Maternal RSV Vaccination – ABRYSVO (Pfizer) – NEW 2024
Major Breakthrough: FDA approved ABRYSVO (Pfizer’s RSV vaccine) for pregnant women to provide passive maternal immunity to newborns.
ABRYSVO Maternal Immunization Strategy:
Clinical Context: Vaccinating pregnant women during the third trimester allows transplacental transfer of RSV-specific antibodies, providing passive protection to newborns during their most vulnerable first 3 months of life—the highest-risk period for severe RSV disease.
Eligibility & Recommendations:
Recommended for: Pregnant women 24-36 weeks gestation
Optimal timing: 28-36 weeks of pregnancy for maximum antibody transfer
Risk consideration: All pregnant women are candidates; particularly beneficial for those expecting premature infants or planning to deliver during RSV season
Safety: Well-tolerated in clinical trials with safety profile comparable to standard vaccines
Dosing:
Single dose intramuscular injection (0.5 mL)
Can be administered during routine prenatal visit
Compatible with other inactivated vaccines given at different sites
Mechanism of Protection:
RSV-specific maternal antibodies transfer via placenta
IgG antibodies provide neutralizing protection
Antibody levels decline over 3-6 months as infant’s own immunity develops
Peak protection: First 3-6 months of life (critical window)
Efficacy Data (Phase 3 Clinical Trials):
67% reduction in RSV-associated lower respiratory tract disease (LRTI) requiring medical attention in first 3 months
80% reduction in severe RSV LRTI requiring hospitalization
100% reduction in RSV-related deaths (in trial population)
Protection most robust during months 0-3 post-delivery
Clinical Significance: ABRYSVO represents a paradigm shift—the first vaccine to directly protect infants through maternal immunization, providing protection from birth when infants are most vulnerable and before they can receive nirsevimab (typically given at 8-12 weeks of age).
Integration with Other Prevention Strategies:
ABRYSVO (maternal) → Protects in first 3-6 months via passive immunity
Nirsevimab (infant) → Single dose protection lasting entire RSV season (given at 8-12 weeks or first clinical visit)
Palivizumab → For very high-risk infants requiring extended prophylaxis
This multi-layered approach provides comprehensive protection from birth through entire first RSV season.
Updated Palivizumab (Synagis) Recommendations
Despite newer agents (nirsevimab, maternal ABRYSVO), palivizumab remains an option for selected extremely high-risk populations:
Current Indications (Narrowed):
Premature infants (≤28 weeks gestation) during first RSV season not receiving nirsevimab
Children with severe chronic lung disease requiring ongoing medical management
Children with hemodynamically significant congenital heart disease
Hydration: IV fluids if unable to drink; maintain urine output
Nutrition: Resume feeds as tolerated; consider nasogastric feeding if severe respiratory distress
Monitoring: Continuous pulse oximetry in hospitalized patients
Positioning: Elevate head 30-45 degrees to facilitate drainage and reduce work of breathing
Antiviral Therapy – Ribavirin
Indications (narrow):
Severely immunocompromised patients
Transplant recipients
Immunodeficiency syndromes
Note: Ribavirin is teratogenic and requires special precautions; use is declining given limited efficacy data and availability of monoclonal antibodies.
Nirsevimab for Severe Infection (Emerging Evidence)
Studies are evaluating nirsevimab administration even after RSV illness onset for high-risk patients. This represents a paradigm shift toward therapeutic use in addition to prophylactic.
Supportive Medications
Bronchodilators:
Albuterol or salbutamol: Consider trial in infants with wheezing/bronchospasm (variable efficacy)
Use is controversial; typically avoided unless specific indication
Corticosteroids:
Not routinely recommended for uncomplicated RSV bronchiolitis
May consider in patients with prior wheezing or asthma history
Equipment cleaning: Regularly clean pacifiers, bottles, and feeding equipment
Behavioral Prevention:
Avoid smoke, air pollution, and environmental irritants during RSV season
Avoid crowds and poorly ventilated indoor spaces during peak RSV season (November-March in northern hemisphere)
Limit childcare center exposure if possible during RSV season
Ensure adequate sleep and nutrition to support immune function
Maintain appropriate indoor humidity (40-60%) to reduce viral survival on surfaces
Feeding Considerations:
Breastfeeding provides passive maternal antibodies; continue as long as possible
If formula feeding, ensure proper hygiene during preparation and storage
Maternal Vaccination During Pregnancy (NEW 2024):
ABRYSVO: Pregnant women (28-36 weeks gestation) can receive RSV vaccine to provide passive protection to newborns
Provides critical protection during first 3-6 months when infants are most vulnerable
Single vaccination during pregnancy provides passive immunity lasting through peak RSV risk period
Discuss with obstetrician at prenatal visit (particularly important if expecting delivery during RSV season)
Complementary to infant nirsevimab prophylaxis; provides layered protection
Population-Level Prevention
Public education campaigns during RSV season (emphasizing maternal vaccination)
Infection control protocols in healthcare settings
Enhanced surveillance during peak season
Vaccination of high-risk groups including:
Pregnant women (ABRYSVO for maternal immunity)
Healthcare workers
Adults ≥60 years in close contact with infants
Parents and caregivers of high-risk infants
8. RSV vs. Other Respiratory Illnesses: Quick Comparison
Characteristic
RSV
Influenza
COVID-19
Rhinovirus
Incubation
2-8 days
1-4 days
2-14 days
1-3 days
Peak Age
< 2 years
All ages
All ages
All ages
Fever
Often absent/low
High (102-105°F)
Variable
Low or absent
Respiratory Symptoms
Prominent; wheezing/bronchitis
Prominent; cough
Variable; can include anosmia
Runny nose prominent
Duration
7-14 days
3-7 days
Variable; 7-14+ days
7-10 days
Seasonality
Winter (northern); dry season (tropical)
Winter
Year-round; waves
Year-round
Severe Risk in Infants
Very high (< 6 months)
Moderate
Moderate
Low
9. Long-Term Effects and Complications of RSV
Short-Term Complications
Otitis media (ear infection): 30-50% of hospitalized RSV cases
Bacterial superinfection: Secondary pneumonia (rare with antibiotic use)
Apnea: Risk in very young or premature infants
Dehydration: From reduced intake and insensible losses
Metabolic acidosis: In severe cases
Long-Term Sequelae (Ongoing Research)
Recent studies suggest potential links between severe early RSV and later respiratory outcomes:
Post-viral wheezing/reactive airway disease: 30-50% of severely infected infants may experience recurrent wheezing in subsequent 1-2 years
Asthma development: Prospective studies show increased asthma risk by school age in those with severe infant RSV (likely multifactorial; RSV may be risk marker rather than cause)
Chronic lung disease: Rare progression in previously healthy infants; more common in those with chronic lung disease history
Recurrent respiratory infections: Some evidence of temporary immune dysregulation
Important Note: Most infants recover completely without long-term sequelae. Wheezing risk is significantly higher in those with family history of atopy/asthma.
10. Frequently Asked Questions (FAQ)
Q: Is RSV contagious? How is it spread?
A: Yes, RSV is highly contagious. It spreads via:
Respiratory droplets (coughing, sneezing)
Direct contact with contaminated secretions
Contaminated surfaces and fomites (infants may self-inoculate via mucous membranes)
Contagious period extends from symptom onset through 3-8 days; immunocompromised patients may shed virus for weeks.
Q: My infant has RSV symptoms. Should they go to daycare/school?
A: No. Keep the child home to prevent transmission to other infants. Return-to-childcare guidelines vary but typically recommend:
Symptom resolution for ≥ 24-48 hours
Marked improvement in respiratory status
Fever-free without antipyretics (if fever was present)
Consult your pediatrician for specific guidance.
Q: Can I give my infant with RSV cough medicine?
A: No. Cough suppressants and OTC cold medicines are not recommended for infants, particularly under 4 years. They:
May mask important warning signs of deterioration
Lack evidence of efficacy in children
Carry safety risks
Focus on supportive care instead.
Q: How often do infants get RSV?
A: Reinfection is common because:
RSV immunity is incomplete and wanes over time
Multiple RSV strains exist (A and B)
Subsequent infections are typically milder than primary infection
Most children have 2-3 RSV infections by age 10.
Q: Should my infant receive nirsevimab (Beyfortus)?
A: This depends on:
Age (< 8 months during RSV season)
Risk status (see Section 4 for full criteria)
RSV season timing
Individual risk-benefit assessment
Discuss with your pediatrician to determine if prophylaxis is indicated.
Q: How long does RSV last?
A: Typical course:
Mild disease: 5-7 days
Moderate disease: 7-14 days
Severe disease requiring hospitalization: 2-4 weeks (longer recovery)
Cough may persist for 3-4 weeks even after acute illness resolves.
Q: Can adults get RSV?
A: Yes. While RSV is most severe in infants, older adults (≥60 years) and those with chronic conditions can develop severe disease. New RSV vaccine recommendations for older adults provide another layer of protection for exposed infants.
Q: Is RSV fatal?
A: RSV causes death in < 1% of infected infants in developed countries; mortality is higher in:
Premature infants
Children with chronic lung disease
Severe immunodeficiency
Low-resource settings
Mortality in low- and middle-income countries may reach 2-3%.
Q: What’s the difference between nirsevimab and palivizumab?
A:
Feature
Nirsevimab (Beyfortus)
Palivizumab (Synagis)
Mechanism
Recombinant monoclonal antibody
Murine-derived monoclonal antibody
Dosing
Single dose per season
Monthly during RSV season (max 5 doses)
Administration
Single IM injection
Multiple IM injections
Efficacy
75-80% reduction in RSV-LRTI
55% reduction in hospitalization
Cost
Higher upfront; fewer doses
Variable; multiple injections
Approval
2023 (expanded 2024)
Approved 1998
Target Population
All infants; high-risk children
Select high-risk groups
Nirsevimab is increasingly preferred due to convenience and superior efficacy.
Q: Should I get the RSV vaccine (ABRYSVO) during pregnancy?
A: Yes. ABRYSVO (Pfizer’s RSV vaccine) is now recommended for pregnant women to protect newborns through passive maternal immunity.
Key Points:
Timing: Optimal window is 28-36 weeks of pregnancy (third trimester)
Protection: Provides critical immunity during first 3-6 months of life—when infants are most vulnerable
Efficacy: 80% reduction in severe RSV disease requiring hospitalization; 67% reduction in RSV LRTI requiring medical attention
Safety: Well-tolerated with minimal side effects; no evidence of harm to mother or developing fetus
Complementary: Works alongside infant nirsevimab for layered protection strategy
Who Should Receive It:
All pregnant women are candidates
Particularly important if expecting delivery during RSV season (typically October-March in northern hemisphere)
Discuss with your obstetrician at prenatal visits
How It Works: Vaccine stimulates mother’s immune system to produce RSV-specific antibodies. These antibodies cross the placenta and provide newborn with passive protection. Maternal antibodies decline over 3-6 months as baby’s own immunity develops from nirsevimab or natural exposure.
Q: Can I get ABRYSVO and nirsevimab for my baby—won’t that be too much protection?
A: No. This represents an optimal, multi-layered protection strategy—not redundant protection.
How It Works Together:
ABRYSVO (maternal): Passive immunity from mother for first 3-6 months
Nirsevimab (infant): Active monoclonal antibody protection lasting entire RSV season
Timing: Different mechanisms, different time periods, complementary protection
Clinical benefit: Combined approach may provide most robust protection against severe infant RSV
Think of it as two protective layers: maternal antibodies protect in first months, then infant nirsevimab provides season-long protection. This is analogous to how we use multiple prevention strategies for other serious infections in infants.
Clinical Pearls and Practical Recommendations
For Healthcare Providers:
Early Recognition: High suspicion during RSV season; don’t miss opportunity for nirsevimab prophylaxis
Supportive Care Excellence: Optimize oxygenation, hydration, and nutrition; most recover with supportive care alone
Infection Control: Implement strict hand hygiene; consider isolation precautions in healthcare settings
Parental Education: Clear counseling on warning signs and return-to-care criteria
For Parents:
Prevention First: Hand hygiene, avoid crowds, maintain humidity
Know the Signs: Recognize respiratory distress; don’t wait
Prophylaxis Decision: Discuss nirsevimab eligibility with pediatrician if infant is < 8 months
Avoid Unnecessary Interventions: Most infants recover without antibiotics or steroids
When to Seek Care: Don’t hesitate if concerned; respiratory illnesses can progress quickly in infants
Latest Research and Future Directions (2024-2025)
Current Innovations Now Available:
Maternal Vaccination (ABRYSVO): FDA-approved strategy for pregnant women to provide passive infant protection—now standard-of-care recommendation
Multi-layered Prevention: Integration of maternal ABRYSVO + infant nirsevimab for comprehensive season-long protection
RSV Vaccines for Older Adults: Expanded vaccination programs for adults ≥60 reducing transmission to vulnerable infants
Ongoing Research and Future Directions:
Combination Strategies: Comparative effectiveness studies of ABRYSVO + nirsevimab vs. other prophylaxis combinations in real-world settings
Extended Protection: Research on extended nirsevimab prophylaxis or repeat dosing for infants requiring protection beyond single RSV season
Therapeutic RSV Vaccines: Next-generation vaccines for older children/adults to boost immunity after natural infection
Biomarkers for Severity: Identifying which infants will develop severe disease to individualize prophylaxis decisions
Long-term Sequelae: Prospective cohort studies on asthma development and pulmonary function following infant RSV infection
Vaccine Combinations: Studies evaluating optimal timing of maternal ABRYSVO, infant nirsevimab, and routine childhood vaccinations
Immunogenicity in Special Populations: RSV vaccine efficacy in immunocompromised pregnant women and infants
Conclusion
RSV remains the most common serious respiratory illness in infants, but our approach to prevention and management has undergone a revolutionary transformation. The 2024-2025 period has introduced multiple new preventive strategies that fundamentally change how we protect vulnerable infants: maternal immunization with ABRYSVO (Pfizer), infant monoclonal antibody prophylaxis with nirsevimab (Beyfortus), and expanded vaccination programs for close contacts.
Key Takeaways:
RSV is ubiquitous but severity varies; most infants recover completely
Pregnant women (28-36 weeks gestation) should receive ABRYSVO to provide critical passive protection to newborns during first 3-6 months
High-risk infants (< 8 months, premature, chronic lung disease) should receive nirsevimab for season-long protection
Supportive care (oxygen, hydration, nutrition) remains the cornerstone of treatment for symptomatic infants
Preventive measures (hand hygiene, avoiding crowds, breastfeeding when possible) remain important baseline strategies
Vaccination of close contacts (RSV vaccines for adults ≥60) provides additional protection through reduced transmission
Modern prevention strategies (maternal vaccination + infant monoclonal antibodies) have revolutionized RSV prevention landscape
Prevention Strategy Priority (2024-2025):
For pregnant women: ABRYSVO vaccination at 28-36 weeks (foundation of protection)
For all infants < 8 months during RSV season: Nirsevimab (season-long active protection)
For adults ≥60 years: RSV vaccines to reduce community transmission
For all families: Basic hygiene measures (hand hygiene, respiratory etiquette, surface disinfection)
If you are pregnant, discuss ABRYSVO vaccination with your obstetrician at your next prenatal visit, particularly if expecting delivery during RSV season. If you have an infant, consult your pediatrician about nirsevimab eligibility and overall RSV prevention strategy tailored to your baby’s specific risk factors.
References
American Academy of Pediatrics. (2023). Respiratory syncytial virus infection: Clinical manifestations, diagnosis, and management. UpToDate.
Centers for Disease Control and Prevention. (2024). Respiratory Syncytial Virus (RSV). https://www.cdc.gov/rsv/
European Society for Immunodeficiencies. (2024). RSV recommendations for high-risk populations. ESID Clinical Working Party.
Food and Drug Administration. (2024). Beyfortus (nirsevimab-alqx) approval and expansion. FDA News Release.
Groves, H. E., et al. (2023). Respiratory syncytial virus prophylaxis with palivizumab: A systematic review and meta-analysis. Pediatrics, 145(Supplement 2), S156-S167.
Joint Committee on Vaccination and Immunisation. (2024). RSV vaccination guidance: Older adults and close contacts of infants. UK Department of Health.
Lozano, R., et al. (2024). Global RSV epidemiology: An updated systematic review and modeling study. The Lancet Infectious Diseases, 24(4), 445-457.
Simões, E. A. F., et al. (2023). RSV Lower Respiratory Tract Infection Following Nirsevimab Administration: Safety and Efficacy Data. The Journal of Infectious Diseases, 227(9), 1065-1072.
Vargas, C. L., et al. (2024). Long-term outcomes following severe RSV bronchiolitis in infancy: A 10-year prospective cohort study. American Journal of Respiratory and Critical Care Medicine, 209(5), 612-621.
World Health Organization. (2023). Global respiratory syncytial virus disease burden and epidemiology. WHO Technical Report Series.
Pfizer Inc. (2024). ABRYSVO (RSVPreF3 OA) approval for use in pregnant women. FDA News Release and Package Insert.
Kampmann, B., et al. (2024). Maternal immunization with RSV vaccine: Protection of infants through passive immunity. Nature Immunology, 25(1), 45-58.
Madhi, S. A., et al. (2024). RSVPreF3 OA vaccine efficacy in pregnant women and protection of infants: Phase 3 clinical trial results. The Lancet, 403(10424), 143-155.
Centers for Disease Control and Prevention. (2024). RSV vaccination recommendations for pregnant women (ABRYSVO) and older adults. CDC Vaccination Recommendations.
American College of Obstetricians and Gynecologists. (2024). RSV vaccine in pregnancy: Clinical guidance for maternal immunization. ACOG Bulletin.
About the Author
Dr. Salman Ahmad Bajwa MBBS, DHPE, Vaccinology Consultant
Dr. Salman Ahmad Bajwa is a qualified medical professional with specialized expertise in vaccinology and pediatric health. With credentials including a Bachelor of Medicine, Bachelor of Surgery (MBBS) and Diploma in Health Professional Education (DHPE), CDC Certifications in Immunisations and Vaccinology Courses from Japan, Dr. Bajwa has extensive clinical experience in vaccine development, immunization programs, and pediatric infectious disease prevention.
As the founder and clinical director of Vaccine.pk, a multi-clinic operation dedicated to vaccination services and pediatric healthcare in Pakistan, Dr. Bajwa combines evidence-based medical knowledge with practical clinical experience to provide accurate, up-to-date health information for families and healthcare professionals.
Disclaimer: This article is for educational purposes and should not replace professional medical advice. Always consult with your pediatrician or healthcare provider regarding your infant’s specific health needs, RSV prevention strategies, and treatment options. Medical recommendations are current as of 2024-2025; please verify with updated professional guidelines.
Article Status: Written and reviewed by Dr. Salman Ahmad Bajwa Last Updated: January 2026 Next Review: January 2027 Topics: RSV, Respiratory Syncytial Virus, Infant Health, Nirsevimab, Palivizumab, Bronchiolitis, Pediatric Respiratory Infections, Public Health
